Dynamics of Carotid Intima-Media Thickness, Parameters of Arterial Stiffness and Ambulatory Blood Pressure Monitoring during Therapy with Inhibitor of Tumor Necrosis Factor-Alpha in Patients with Early Psoriatic Arthritis
Background. Patients with psoriatic arthritis (PsA) have increased risk of cardiovascular diseases (CVD). Anti-tumor necrosis factor (TNF) therapy is an effective in PsA but its cardiovascular effects are poorly understood.Aim. To study the changes in carotid intima-media thickness (c-IMT), paramete...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Book |
Published: |
Столичная издательская компания,
2018-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_c0e87865abea46ebb35ed8c74b11a15f | ||
042 | |a dc | ||
100 | 1 | 0 | |a E. I. Markelova |e author |
700 | 1 | 0 | |a D. S. Novikova |e author |
700 | 1 | 0 | |a T. V. Korotaeva |e author |
700 | 1 | 0 | |a E. Yu. Loginova |e author |
245 | 0 | 0 | |a Dynamics of Carotid Intima-Media Thickness, Parameters of Arterial Stiffness and Ambulatory Blood Pressure Monitoring during Therapy with Inhibitor of Tumor Necrosis Factor-Alpha in Patients with Early Psoriatic Arthritis |
260 | |b Столичная издательская компания, |c 2018-11-01T00:00:00Z. | ||
500 | |a 1819-6446 | ||
500 | |a 2225-3653 | ||
500 | |a 10.20996/1819-6446-2018-14-5-711-715 | ||
520 | |a Background. Patients with psoriatic arthritis (PsA) have increased risk of cardiovascular diseases (CVD). Anti-tumor necrosis factor (TNF) therapy is an effective in PsA but its cardiovascular effects are poorly understood.Aim. To study the changes in carotid intima-media thickness (c-IMT), parameters of arterial stiffness (AS), ambulatory blood pressure monitoring (AMBP) in early PsA (EPsA) patients during the anti-TNF therapy with adalimumab (ADA).Material and methods. Patients with EPsA (n=16; 11 females, 5 males; median age 45.5 years, EPsA duration - 7.7 months) were included into the study. All patients were treated with ADA 40 mg every other week up to 3 months. At baseline and after 3 months of therapy all patients were assessed for conventional cardiovascular risk factors, DAS (Disease Activity Score) and HAQ (Health Assessment Questionnaire) indices, C-reactive protein (CRP), c-IMT, ABPM. At baseline the 4 patients had arterial hypertension, and all patients received effective antihypertensive therapy. All patients were assessed for AS parameters: carotid-femoral pulse wave velocity (PWVcf) and index of wave reflection (rigidity index; RI, %). c-IMT was measured using a high-resolution B-mode ultrasound machine. The results are presented in the form of a median - Me (25; 75 percentiles).Results. By the end of the 3rd month of therapy, a decrease in the activity of early PsA was observed as compared to baseline values: DAS decreased from 4.6 (2.9; 1.9) to 1.6 (1.3; 1.9), p=0,001; HAQ from 0.93 (0.81; 1.31) to 0.25 (0; 0.56), p=0,001; CRP from 27.2 (9.7; 33.7) to 1.8 (0.8; 3.1) mg/l, p=0.001. EPsA remission (DAS<1.6) was achieved in 94% of patients. By the end of therapy c-IMT decreased from 0.8 (0.74; 0.85) to 0.73 (0.58; 0.77) mm, p=0,01; as well as AS parameters: PWVcf from 9.9 (7.7; 17.7) to 9.2 (7.4; 10.6) m/s, p<0.05; RI from 69.5 (58; 74) to 49.5 (44; 64)%, p<0.05. AMBPs parameters didn't change significantly. We found significant (p=0.03) decrease in the frequency of the increase in 24-hour diastolic blood pressure.Conclusions. Anti-TNF treatment with ADA improves arterial wall state by decreasing inflammation. These data confirm the idea that inflammation involves in acceleration of atherosclerosis in EPsA patients. | ||
546 | |a EN | ||
546 | |a RU | ||
690 | |a early psoriatic arthritis | ||
690 | |a inhibitor of tumor necrosis factor-alpha | ||
690 | |a carotid intima-media thickness | ||
690 | |a arterial stiffness | ||
690 | |a ambulatory blood pressure monitoring | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
690 | |a Diseases of the circulatory (Cardiovascular) system | ||
690 | |a RC666-701 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Рациональная фармакотерапия в кардиологии, Vol 14, Iss 5, Pp 711-715 (2018) | |
787 | 0 | |n https://www.rpcardio.online/jour/article/view/1760 | |
787 | 0 | |n https://doaj.org/toc/1819-6446 | |
787 | 0 | |n https://doaj.org/toc/2225-3653 | |
856 | 4 | 1 | |u https://doaj.org/article/c0e87865abea46ebb35ed8c74b11a15f |z Connect to this object online. |